Everyman past successes
With your help our scientists have already made a huge difference to men with prostate and testicular cancer.
So far they have:
- Completely changed the management of prostate cancer by introducing the concept of Active Surveillance. This is now the NICE (National Institute for Health and Clinical Excellence) recommended management of patients with localised non-aggressive prostate cancer.
- Developed and tested the prostate cancer drug abiraterone, which has shown promising results in early clinical trials and for which we are currently awaiting the definitive results from the final phase of the clinical studies.
- Over the past two years, our scientists have identified numerous new genetic variants that increase a man’s risk of developing prostate cancer, leading to a greater understanding of their susceptibility to the disease.
Dramatically improved prostate cancer radiotherapy through the development of conformal and intensity modulated techniques, resulting in both increased cancer control and fewer side effects for patients. We have proved that higher doses of radiotherapy improve prostate cancer remission rates by 30%.- Discovery of the first inherited genetic variants for testicular cancer, which can increase a man’s risk of developing testicular cancer by two to three-fold.
- Identification of three genetic abnormalities that in combination significantly impact how long a prostate cancer patient is likely to survive with the disease. This is one of a number of promising biological markers for prostate cancer that is being investigated as a way to more accurately diagnose the tumour and assess the patients' response to treatment.
- Developed the drug carboplatin which has helped lead to a 99% cure rate for testicular cancer and is also widely used in ovarian, lung, head, neck and bladder cancers.
